摘要
目的:系统评价利多卡因与胺碘酮治疗严重室性心律失常的疗效及安全性。方法:通过电子检索5个数据库,纳入利多卡因与胺碘酮治疗严重室性心律失常的所有随机对照试验,逐个进行质量评价和资料提取,并进行Meta分析。结果:符合纳入标准的文章8篇,2个试验被排除;最后共6个试验包括674例患者符合纳入标准进入本系统评价。Meta分析结果显示:①总有效率:胺碘酮优于利多卡因(P<0.001);②病死率:差异无统计学意义(P>0.05);③药物不良反应发生率:利多卡因低于胺碘酮(P<0.05)。结论:本系统评价显示在治疗严重室性心律失常疗效方面,胺碘酮优于利多卡因;在降低患者病死率两者差异无统计学意义;在药物不良反应发生率方面,胺碘酮高于利多卡因。
Objective: To evaluate the effect and safety of Lidocaine and Amiodarone on patients with malignant ventricular arrhythmia. Method: Five databases about Lidocaine and Amiodarone treated malignant ventricular arrhythmia were collected, and metaanalysis was performed. Result: After the titles and abstracts were readed, six trials which included 674 patients were performed system evaluation. The result of meta-analysis shown : total effective rate, Lidocaine was worse than Amiodarone ( P〈0.001) ; fatality rate (P=0.61) ; ADR rate, Lidocaine was better than Amiodarone(P〉0.05 ). Conclusion: On the aspect of treating malignant ventricular arrhythmia, Lidocaine is more inferior than Amiodarone ; on fatality rate, there are no statistical significance; on safety, Lidocaine is better than Amiodarone.
出处
《中国药师》
CAS
2008年第1期31-35,共5页
China Pharmacist
关键词
利多卡因
胺磺酮
恶性室性心律失常
系统评价
Lidocaine
Amiodarone
Malignant ventricular arrhythmia
System evaluation